High-density lipoprotein-associated sphingosine-1-phosphate activity in heterozygous familial hypercholesterolaemia

Eur J Clin Invest. 2017 Jan;47(1):38-43. doi: 10.1111/eci.12699. Epub 2016 Nov 30.

Abstract

Background: Patients with heterozygous familial hypercholesterolaemia (FH) suffer from high plasma cholesterol and an environment of increased oxidative stress. We examined its potential effects on high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) content (HDL-S1P) and HDL-mediated protection against oxidative stress, both with and without statin treatment.

Materials and methods: In a case-control study, HDL was isolated from 12 FH patients with and without statin treatment and from 12 healthy controls. The HDL-S1P content and the capacity of HDL to protect cardiomyocytes against oxidative stress in vitro were measured.

Results: HDL-associated S1P was significantly correlated with cell protection, but not with HDL-cholesterol or apolipoprotein AI. The latter did not correlate with HDL-mediated cell protection. Neither the HDL-S1P content nor HDL protective capacity differed between nontreated FH patients and controls. The relative amounts of apolipoprotein AI and apolipoprotein M were similar between controls and FH patients. Statin treatment had no effect on any of these measures.

Conclusions: The FH environment is not detrimental to HDL-S1P content or HDL-S1P-mediated cell protection. Statin treatment does not modulate HDL function in this regard.

Keywords: Apolipoprotein M; cardiomyocyte; high-density lipoprotein; oxidative stress; sphingosine-1-phosphate.

MeSH terms

  • Adult
  • Animals
  • Apolipoprotein A-I / metabolism*
  • Case-Control Studies
  • Cells, Cultured
  • Cholesterol, HDL / metabolism
  • Chromatography, Liquid
  • Female
  • Heterozygote
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hyperlipoproteinemia Type II / drug therapy
  • Hyperlipoproteinemia Type II / metabolism*
  • In Vitro Techniques
  • Lipoproteins, HDL / metabolism*
  • Lipoproteins, HDL / pharmacology
  • Lysophospholipids / metabolism*
  • Male
  • Middle Aged
  • Myocytes, Cardiac / drug effects
  • Oxidative Stress* / drug effects
  • Rats
  • Sphingosine / analogs & derivatives*
  • Sphingosine / metabolism
  • Tandem Mass Spectrometry
  • Young Adult

Substances

  • Apolipoprotein A-I
  • Cholesterol, HDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipoproteins, HDL
  • Lysophospholipids
  • sphingosine 1-phosphate
  • Sphingosine